• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

RCT Results: Does Fractional Laser Therapy Actually Improve Postmenopausal Vaginal Symptoms?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Efficacy of fractional carbon dioxide vaginal laser is not well established for postmenopausal symptoms
  • Li et al. (JAMA, 2021) sought to determine the efficacy of fractional carbon dioxide laser for treatment of vaginal symptoms associated with menopause

METHODS:

  • Double-blind, randomized, sham-controlled trial
  • Participants
    • Postmenopausal women | Amenorrheic for at least 12 months,
    • Vaginal symptoms (≥ 1 symptoms including dyspareunia, burning, itching, or dryness) requiring medical treatment
  • Interventions
    • Microablative carbon dioxide laser treatment 
    • Sham
  • Study design
    • Laser treatment: 3 treatments | Performed 4 to 8 weeks apart | 12-month follow-up
    • Sham:  Minimal energy settings with no tissue effect | Visual and auditory effects from the laser were identical to that of treatment
  • Sample size calculation
    • Minimal clinically important difference: 50% decrease in both
      • Visual analog scale (VAS; range, 0 to 100; 0 indicates no symptoms and 100 indicates most severe symptoms)
      • Vulvovaginal Symptom Questionnaire (VSQ; range, 0 to 20; 0 indicates no symptoms and 20 indicates most severe symptoms)
    • Assume 30% placebo effect
    • Sample size was increased to 78 to reduce the probability of a type II error and participant drop out
  • Primary outcomes
    • Symptom severity at 12 months
      • VAS
      • VSQ
  • Secondary outcomes
    • Quality of life (range 0 to 100)
    • Vaginal Health Index Score (range 5 to 25)
    • Vaginal histology (premenopausal or postmenopausal status)

RESULTS:

  • 85 randomized participants
    • Mean (SD) age: 57 (8) years | 91.7% completed follow-up
  • At 12 months, there was no significant difference between the groups in change in symptom severity
    • VAS score for overall vaginal symptoms
      • Laser: –17.2
      • Sham: –26.6
      • Difference 9.4 (95% CI, –28.6 to 47.5)
    • VAS score for the most severe symptom
      • Laser: –24.5
      • Sham: –20.4
      • Difference –4.1 (95% CI, –32.5 to 24.3)
    • VSQ score
      • Laser: –3.1
      • Sham: –1.6
      • Difference –1.5 (95% CI, –5.9 to 3.0)
  • There were no significant differences between the laser and sham group in
    • Mean quality of life score
      • Laser: 6.3
      • Sham: 1.4
      • Difference 4.8 (95% CI, –3.9 to 13.5)
    • Vaginal Health Index Score
      • Laser: 0.9
      • Sham: 1.3
      • Difference –0.4 (95% CI, –4.3 to 3.6)
    • Histological comparisons
  • Incidence of adverse events
    • Laser: 16 events
    • Sham: 17 events
    • There were no severe adverse events in either group
  • Adverse events
    • Vaginal pain/discomfort
      • Laser: 44%
      • Sham: 68%
    • Spotting
    • Discharge
    • Lower urinary tract symptoms

CONCLUSION:

  • There was no improvement in postmenopausal vaginal symptoms 12 months after fractional carbon dioxide laser treatment vs sham treatment
  • The authors state

Clinical outcomes and cost-effectiveness of treatments, whether devices or drugs, should be evaluated rigorously prior to integration into routine treatment

The annual cost of laser treatment to the individual for management of vaginal menopausal symptoms was reported to be $2733.24 and because there is no demonstratable difference vs sham treatment, it cannot be considered to be cost-effective

Learn More – Primary Sources:

Effect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

VeLVET Trial: Does Laser Therapy Work for Treating Vaginal Atrophy in Menopause?
Laser Therapy for Urinary Incontinence and Pelvic Organ Prolapse: What is the Evidence?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site